Silexion Therapeutics (SLXN) Expected to Release Quarterly Earnings on Tuesday

by · The Cerbat Gem

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) is anticipated to post its results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($21.20) per share for the quarter.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($12.90) by $12.05.

Silexion Therapeutics Price Performance

SLXN traded down $0.23 during trading on Tuesday, reaching $1.72. 557,479 shares of the company’s stock were exchanged, compared to its average volume of 285,742. Silexion Therapeutics has a 1 year low of $1.50 and a 1 year high of $90.45. The stock has a market capitalization of $718,585.00, a P/E ratio of -0.02 and a beta of -0.26. The company’s fifty day simple moving average is $3.05 and its 200-day simple moving average is $9.84.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SLXN shares. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Silexion Therapeutics currently has a consensus rating of “Hold”.

View Our Latest Research Report on SLXN

Silexion Therapeutics Company Profile

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Featured Articles